.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

PARP Inhibition in Recurrent Prostate Cancer

EP. 1: Diagnosis of Prostate Cancer

September 28th 2020

EP. 2: Genetic Counseling for Prostate Cancer

September 28th 2020

EP. 3: Impact of BRCA Mutations in Prostate Cancer

September 28th 2020

EP. 4: FDA-Approved PARP Inhibitors for Prostate Cancer

September 28th 2020

EP. 5: Quality of Life With Prostate Cancer

September 28th 2020

EP. 6: Patient’s Role in Decision-Making for Prostate Cancer

September 28th 2020

EP. 7: The Future of PARP Inhibitors in Prostate Cancer

September 28th 2020

EP. 8: Metastatic Castration-Resistant Prostate Cancer Overview

September 28th 2020

EP. 9: Receiving a Prostate Cancer Diagnosis

September 28th 2020

EP. 10: Prostate Cancer: Learning About Treatment Options

September 28th 2020

EP. 11: Testing for Mutations in Prostate Cancer

September 28th 2020

EP. 12: Talking About Gene Testing in Prostate Cancer

September 28th 2020

EP. 13: John Litten: Participating on a PARP Clinical Trial for mCRPC

September 28th 2020

EP. 14: Treatment Options Available for mCRPC

September 28th 2020

EP. 15: PARP Inhibitors in Recurrent mCRPC

September 28th 2020

EP. 16: Advice to Patients Facing mCRPC

September 28th 2020

EP. 17: Future Use of PARP Inhibition in Prostate Cancer

September 28th 2020

EP. 18: Advances in Prostate Cancer

September 28th 2020

Latest News

My Mastectomy Results Were Not What I Expected

Cancer Survivors, Loved Ones Share How They Advocate

Recognizing Psychological Distress After Cancer

HER2-Positive Breast Cancer Needs Aggressive Treatment, Expert Says

View More Latest News